People · Operator
Named in public records as an officer, director or promoter · active 2010–2019 · Pharmaceuticals, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $73.2M | $1.2B | 2015 |
| Scholar Rock LLC | — | Biotechnology | Series B | $36.3M | $1.4B | 2015 |
| Obsidian Therapeutics, Inc. | — | Biotechnology | Series B | $32.4M | $1.3B | 2017 |
| Arrakis Therapeutics, Inc. | — | Biotechnology | Series A | $28.2M | $542.3M | 2017 |
| Stromedix Inc | — | Pharmaceuticals | Seed | $2.0M | $76.1M | 2011 |
| Gene Network Sciences, Inc. | — | Other Technology | Pre-Seed | $450K | $19.1M | 2010 |
Michael Gilman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Gilman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barrett | 2 | 18 |
| Alan E. Walts | 2 | 3 |
| Kristina Burow | 1 | 16 |
| Isaac Blech | 1 | 14 |
| Amir Nashat | 1 | 14 |
| David Neafus | 1 | 7 |
| Richard Gaster | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Stephen Kraus | 1 | 7 |
| JASON GARDNER | 1 | 5 |
| Michael Wyzga | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Katrine Bosley | 1 | 4 |
| Karen Hong | 1 | 4 |
| Alan Walts | 1 | 3 |
| Nikola Trbovic | 1 | 3 |
| IYA KHALIL | 1 | 3 |
| Adam Mostafa | 1 | 3 |
| Timothy Springer | 1 | 3 |
| Alison Lawton | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.